These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10591875)

  • 1. Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys.
    Fernández-Ruiz J; Doudet D; Aigner TG
    Psychopharmacology (Berl); 1999 Nov; 147(1):104-7. PubMed ID: 10591875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958.
    Andringa G; Lubbers L; Drukarch B; Stoof JC; Cools AR
    Behav Pharmacol; 1999 Mar; 10(2):175-82. PubMed ID: 10780830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment.
    Schneider JS; Van Velson M; Menzaghi F; Lloyd GK
    Ann Neurol; 1998 Mar; 43(3):311-7. PubMed ID: 9506547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
    Lieu CA; Deogaonkar M; Bakay RA; Subramanian T
    Parkinsonism Relat Disord; 2011 Jan; 17(1):34-9. PubMed ID: 21074478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
    Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum.
    Herrero MT; Augood SJ; Hirsch EC; Javoy-Agid F; Luquin MR; Agid Y; Obeso JA; Emson PC
    Neuroscience; 1995 Oct; 68(4):1189-98. PubMed ID: 8544992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
    Irifune M; Nomoto M; Fukuda T
    Eur J Pharmacol; 1994 Oct; 264(2):117-23. PubMed ID: 7851473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPTP-Induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose.
    Emborg-Knott ME; Domino EF
    Exp Neurol; 1998 Aug; 152(2):214-20. PubMed ID: 9710520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.
    Ouattara B; Gasparini F; Morissette M; Grégoire L; Samadi P; Gomez-Mancilla B; Di Paolo T
    J Neurochem; 2010 May; 113(3):715-24. PubMed ID: 20132464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
    Graham WC; Sambrook MA; Crossman AR
    Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rest tremor in rhesus monkeys with MPTP-induced parkinsonism.
    Emborg ME; Tetrud JW; Moirano J; McLaughlin WW; Bankiewicz KS
    Front Biosci; 2003 May; 8():a148-54. PubMed ID: 12700090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of Antiparkinsonian Effects of Systemic Injections of the Specific T-Type Calcium Channel Blocker ML218 in MPTP-Treated Monkeys.
    Galvan A; Devergnas A; Pittard D; Masilamoni G; Vuong J; Daniels JS; Morrison RD; Lindsley CW; Wichmann T
    ACS Chem Neurosci; 2016 Nov; 7(11):1543-1551. PubMed ID: 27596273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys.
    Schneider JS; Tinker JP; Van Velson M; Menzaghi F; Lloyd GK
    J Pharmacol Exp Ther; 1999 Aug; 290(2):731-9. PubMed ID: 10411585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model.
    Decamp E; Schneider JS
    Brain Res; 2009 Mar; 1262():109-14. PubMed ID: 19368843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical activity sustains memory retrieval in dopamine-depleted mice previously treated with L-Dopa.
    Iggena D; Klein C; Rasińska J; Sparenberg M; Winter Y; Steiner B
    Behav Brain Res; 2019 Sep; 369():111915. PubMed ID: 30998993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.